In case of a black widow bite, what can you do?

New antibodies discovered – with fewer side effects and without animal testing

14-Jun-2024 - Black widows spiders are present worldwide with different species. The European black widow (Latrodectus tredecimguttatus) is found in Europe, for example in the Mediterranean region. It prefers to live in dry areas, i.e. regions with low rainfall, high temperatures and dry soils. The female’s ...

Biocytogen Expands Partnership with Merck

29-Aug-2022 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. entered into a global licensing agreement with Merck for the use of Biocytogen’s RenMiceTM platform. Under the terms of the agreement, Merck will have full access to Biocytogen’s RenMiceTM platform to discover and develop fully human antibody ...

CORAT Therapeutics obtained regulatory authorization for clinical phase Ib/II trial with the SARS-CoV-2 neutralizing human antibody COR-101

COR-101 is a human antibody that blocks virus infection by binding to the spike protein

17-Mar-2021 - CORAT Therapeutics GmbH obtained the regulatory approval as well as the favorable opinion from the central ethics committee to conduct the clinical phase Ib/II trial with its antibody COR-101 against COVID-19. COR-101 is a neutralizing human antibody that binds to the receptor binding domain ...

Scientists show we don´t need horses to treat diphtheria

24-Jan-2020 - A project taking the first steps towards replacing the only treatment for diphtheria has succeeded. Funded by the PETA International Science Consortium Ltd. and carried out at the Institute of Biochemistry, Biotechnology, and Bioinformatics at the Technische Universität Braunschweig in Germany, ...

World's first protective antibodies against Marburg virus developed

31-Mar-2017 - A team of scientists around Professor Michael Hust from the Institute of Biochemistry, Biotechnology and Bioinformatics of the Technische Universität Braunschweig developed successfully a panel of antibodies against highly-pathogenic Marburg virus. These are the worldwide first recombinant ...

Early study finds antibody that ‘neutralizes’ Zika virus

09-Nov-2016 - Researchers at Vanderbilt University Medical Center and Washington University School of Medicine in St. Louis have isolated a human monoclonal antibody that in a mouse model “markedly reduced” infection by the Zika virus. The antibody, called ZIKV-117, also protected the fetus in pregnant mice ...

MorphoSys and Galapagos Advance Joint Antibody Program in Inflammatory Diseases into Preclinical Development

25-Jul-2014 - MorphoSys AG and Galapagos NV announced that the first program from their strategic alliance has advanced into preclinical development. MOR106 was realized based on a novel Galapagos target and MorphoSys' next-generation antibody library Ylanthia and will now be jointly developed in inflammatory ...

arGEN-X advances third therapeutic antibody program into preclinical development

10-Feb-2012 - arGEN-X announced that it has progressed ARGX-111, its third therapeutic candidate, into formal preclinical development.ARGX-111 is a novel, fully human antibody specific for c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis. c-Met is widely implicated ...

MorphoSys Strengthens Patent Position on MOR202 Program

25-Jan-2012 - MorphoSys AG announced that the US Patent and Trademark Office (USPTO) has granted a patent covering the Company's cancer compound MOR202. The new patent (US 8,088,896) covers MorphoSys's HuCAL antibody against CD38 as well as pharmaceutical compositions comprising the same, and has a scheduled ...

Genmab announces progress with Lundbeck collaboration

First pre-clinical milestone met in Lundbeck collaboration

19-Dec-2011 - Genmab A/S announced it had reached the first pre-clinical milestone in the collaboration with H. Lundbeck A/S, triggering a €1 million payment. Genmab has reached the first milestone in the collaboration with H. Lundbeck A/S to create and develop human antibody therapeutics for disorders of the ...